ImmuCell Corp (ICCC)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$9.90-1.00%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ICCC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 69.8% |
| Our one-year growth estimate | diamond | -30.3% |
Growth built into the price is above our model estimate.
The price assumes 100.2 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
ICCC — litigation filed
Dated 2026-06-10
Regulation FD Disclosure In late December 2025 and early January 2026, ImmuCell Corporation (“ImmuCell” or the “Company”) announced the suspension of plans to manufacture its Re-Tain® product in-house, and instead convert most of the related facilities and equipment for expanded production of the Company’s flagship First Defense® product line. On June 4, 2026, ImmuCell’s Board of Directors authorized a manufacturing capacity expansion program to execute on that strategy. The first phase, whic…
Why it matters: This investment is vital for scaling production to meet future demand for First Defense.
Supportive ifThe company will announce the start of the colostrum investment in six months.
Worry ifThe company delays or cancels the investment plans.
Why it matters: Watching revenue growth after the peak season helps us understand sales trends.
Worry ifQ3 2026 revenue growth was below 10% from last year. This shows moderation.
Less concerning ifQ3 2026 revenue growth was above 10% from last year. This suggests strong demand.
Why it matters: A positive outcome could improve financial health and help with growth plans.
Supportive ifNo new legal disputes come up about Re-Tain®.
Worry ifNew legal disputes about Re-Tain® may arise.
Why it matters: Lawsuit results can affect how the company runs and its financial health.
Worry ifA good outcome or settlement of the lawsuit that helps operations.
Less concerning ifA bad ruling or long lawsuit that slows down production plans.
Why it matters: Completing this expansion is key to increasing production capacity for First Defense. It supports long-term growth plans.
Supportive ifThe freeze-drying expansion will finish by mid-2027.
Worry ifThe freeze-drying expansion may be delayed past mid-2027.
Why it matters: Growing production capacity is important. It helps meet future demand and boosts revenue.
Supportive ifThe first phase of the production capacity growth is now complete.
Worry ifDelays or problems with the production capacity growth plan.
Why it matters: More international sales mean stronger global demand. This shows the market is getting better.
Supportive ifInternational sales grow by at least 20% compared to Q2 2026.
Worry ifInternational sales keep falling or stay the same compared to Q2 2026.
Why it matters: Litigation outcomes can change future product plans and finances. They may affect investor trust.
Watch forA positive outcome in litigation clears the way for future product plans.
Also watch forA bad result in the lawsuit could lead to delays or changes in product plans.
Why it matters: Growth in product sales shows strong demand. It means the company is fixing past backorder issues.
Supportive ifQ3 product sales growth exceeds 10% year over year.
Worry ifQ3 product sales growth falls below 5% year over year.
Why it matters: A drop in gross margin may mean rising costs or production problems. This can hurt profits.
Worry ifGross margin remains above 33% in Q3.
Less concerning ifGross margin falls below 33% in Q3.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$132 on $10,000 · ±1.3% | How much price usually moves either way. |
| Bad day | $532 loss on $10,000 · 5.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,294 loss on $10,000 · 32.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.